Lilly rises after boosting 2026 outlook [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
pharma giant raised its full-year outlook alongside better-than-expected Q1 2026 financials driven by its GLP-1 franchise. Novo Nordisk ( NVO ), its rival Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters Sign Up Quick Insights Eli Lilly's increased guidance for revenue and EPS is seen as a positive, potentially returning the company to a $1 trillion market capitalization and reinforcing its leadership in pharma valuation. Growth was chiefly driven by strong volume gains in the GLP-1 franchise, including outsized sales of Mounjaro and Zepbound, offsetting some lower realized prices. Analysts believe Mounjaro could become the world's top-selling drug, strongly supporting Lilly's performance along with Zepbound. Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk: Pricing Pressure And Falling Margins Make This A Value Trap (Q1 Earnings Preview) [Seeking Alpha]Seeking Alpha
- What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer. [Yahoo! Finance]Yahoo! Finance
- Jim Cramer Believes “Novo Nordisk Is Going to Lose a Lot of Share on the Pill to Eli Lilly” [Yahoo! Finance]Yahoo! Finance
- Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website